KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal Shah, Roch Houot, Armin Ghobadi et al.|The Lancet|2021Cited by 795
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)Sattva S. Neelapu, Frederick L. Locke, Armin Ghobadi et al.|Blood|2023Cited by 238
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal Shah, Roch Houot, Armin Ghobadi et al.|Journal of Hematology & Oncology|2022Cited by 78
Association between composite dietary antioxidant index and fatty liver index among US adultsMeng Zheng, Jinghui Dong, Chaochen Li et al.|Frontiers in Nutrition|2024Cited by 9
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s LymphomaMagali Chartier, Rhine R. Shen, Simone Filosto et al.|Clinical Pharmacokinetics|2024Cited by 5